A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer

Clinical Ovarian and Other Gynecologic Cancer Pub Date : 2013-12-01 DOI:10.1016/j.cogc.2014.06.002

Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin, Sergei Tjulandin

{"title":"A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer","authors":"Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin, Sergei Tjulandin","doi":"10.1016/j.cogc.2014.06.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>This study was aimed at evaluating the efficacy and tolerability of oxaliplatin/doxorubicin combination therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer.</p></div><div><h3>Materials and Methods</h3><p>Patients with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m<sup>2</sup> intravenously) and oxaliplatin (130 mg/m<sup>2</sup> intravenously) on day 1 every 3 weeks. The platinum-free interval was set to be < 24 months.</p></div><div><h3>Results</h3><p>A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive relapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4% vs. 54.5%), although the difference was not statistically significant (<em>P</em> = .59). The median progression-free survival (PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach statistical significance (<em>P</em> = .14).</p></div><div><h3>Conclusion</h3><p>The combination of oxaliplatin/doxorubicin is an active regimen for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.</p></div>","PeriodicalId":100274,"journal":{"name":"Clinical Ovarian and Other Gynecologic Cancer","volume":"6 1","pages":"Pages 11-16"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cogc.2014.06.002","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Ovarian and Other Gynecologic Cancer","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221295531400026X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction

This study was aimed at evaluating the efficacy and tolerability of oxaliplatin/doxorubicin combination therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer.

Materials and Methods

Patients with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m² intravenously) and oxaliplatin (130 mg/m² intravenously) on day 1 every 3 weeks. The platinum-free interval was set to be < 24 months.

Results

A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive relapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4% vs. 54.5%), although the difference was not statistically significant (P = .59). The median progression-free survival (PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach statistical significance (P = .14).

Conclusion

The combination of oxaliplatin/doxorubicin is an active regimen for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.

查看原文本刊更多论文

奥沙利铂/阿霉素联合治疗复发性卵巢癌的II期非随机研究

本研究旨在评价奥沙利铂/阿霉素联合治疗铂敏感和铂耐药卵巢癌患者的疗效和耐受性。材料与方法卵巢癌复发患者经1个铂类化疗方案后，每3周第1天给予阿霉素(50 mg/m2静脉注射)和奥沙利铂(130 mg/m2静脉注射)。无铂间隔设为<24个月。结果共纳入33例患者，其中铂耐药21例，铂敏感复发12例。铂耐药卵巢癌的缓解率低于铂敏感疾病(33.4%比54.5%)，但差异无统计学意义(P = 0.59)。整个队列的中位无进展生存期(PFS)和总生存期分别为7.4个月和24.3个月。铂敏感性癌症的PFS比铂耐药癌症的PFS更长(10.8个月对6.7个月);但差异无统计学意义(P = .14)。结论奥沙利铂/阿霉素联合治疗铂敏感和铂耐药的复发性卵巢癌是一种有效的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Ovarian and Other Gynecologic Cancer

自引率

0.00%

发文量